Immunovant, Inc.
IMVT
$25.75
$0.110.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.96% | -5.19% | 38.37% | 36.10% | 49.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.05% | 13.84% | 34.94% | 40.73% | 85.70% |
| Operating Income | -0.05% | -13.84% | -34.94% | -40.73% | -85.70% |
| Income Before Tax | 1.70% | -15.47% | -37.47% | -40.99% | -115.37% |
| Income Tax Expenses | 921.05% | 661.54% | 1,085.71% | 151.29% | 240.74% |
| Earnings from Continuing Operations | 0.44% | -15.93% | -38.40% | -41.33% | -116.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.44% | -15.93% | -38.40% | -41.33% | -116.11% |
| EBIT | -0.05% | -13.84% | -34.94% | -40.73% | -85.70% |
| EBITDA | -0.05% | -13.84% | -34.94% | -40.71% | -85.71% |
| EPS Basic | 19.41% | 2.21% | -18.32% | -23.20% | -112.56% |
| Normalized Basic EPS | 20.44% | 2.60% | -17.53% | -22.89% | -111.89% |
| EPS Diluted | 19.41% | 2.21% | -18.32% | -23.20% | -112.56% |
| Normalized Diluted EPS | 20.44% | 2.60% | -17.53% | -22.89% | -111.89% |
| Average Basic Shares Outstanding | 23.54% | 18.55% | 16.97% | 14.71% | 1.66% |
| Average Diluted Shares Outstanding | 23.54% | 18.55% | 16.97% | 14.71% | 1.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |